Access Restricted for EU Residents
You are attempting to access a website operated by an entity not regulated in the EU. Products and services on this website do not comply with EU laws or ESMA investor-protection standards.
As an EU resident, you cannot proceed to the offshore website.
Please continue on the EU-regulated website to ensure full regulatory protection.
Tuesday Jun 2 2026 00:00
3 min
In a landmark development for the robotics industry, Ubtech Robotics, a distinguished name in the field of humanoid robots, has successfully navigated the review by the Listing Committee of the Shanghai Stock Exchange on June 1st. This achievement propels the company closer to becoming the "first A-share listed humanoid robot company," reflecting growing confidence in the sector's potential.
According to its IPO prospectus, Ubtech Robotics aims to raise approximately CNY 4.202 billion. These funds are earmarked for strategic investments primarily focused on enhancing the company's capabilities in intelligent robot model research and development, refining robot body design and architecture, innovating new intelligent robot products, and establishing a state-of-the-art intelligent robot manufacturing base. This strategic allocation underscores the company's long-term vision for scaling operations and fortifying its competitive standing.
Notably, Ubtech Robotics' progression through the Shanghai Stock Exchange's IPO process has been notably swift. The company received initial acceptance on March 20th and subsequently passed the committee's review on June 1st, indicating a timeline of just over two months. This pace ranks among the faster IPO trajectories observed on the STAR Market (科创板) in recent years. Reviewing the disclosed financial data, the company has demonstrated significant performance growth. In 2025, its operating revenue reached approximately CNY 1.7 billion, with a gross profit margin for its core business exceeding 60%. The contribution of its humanoid robot business has rapidly increased, emerging as a new core growth engine for the company.
Ubtech Robotics adheres to a steadfast strategy centered on the in-house development of core robot components, motion control systems, and complete system modules. This commitment has culminated in the formation of a comprehensive product portfolio encompassing both quadrupedal and humanoid robots. Publicly available data indicates that cumulative sales for its quadrupedal robots have surpassed 30,000 units, while humanoid robot sales have reached over 5,600 units. This widespread adoption highlights the company's capacity to meet diverse market demands.
A significant driver behind the heightened interest in Ubtech Robotics' IPO is the current phase of commercial validation within the humanoid robot industry. The company recently unveiled its "WVLA 2.0" embodied AI model and showcased the G1 robot's autonomous capability in tasks such as tidying a meeting room. Furthermore, a Japanese airline has initiated airport ground handling tests using Ubtech's G1 robots, signaling a tangible shift in applications from laboratory settings to actual production environments.
Concurrently, the robotics industry chain in China is experiencing a marked acceleration in funding, listings, and production capacity expansion. With the ongoing integration of large language models, motion control, and hardware components, capital market expectations for the industrialization of embodied intelligence are steadily rising.
Despite these successes, the IPO prospectus also reveals a slowdown in Ubtech Robotics' revenue growth in the first quarter of 2026 compared to previous periods, along with a year-on-year decrease in net profit after deducting non-recurring items. This is primarily attributed to increased R&D investments and higher sales expenses. The company anticipates continued revenue growth in the first half of the year, but its profitability levels are expected to remain influenced by sustained R&D expenditures. Following its IPO approval, Ubtech Robotics still needs to complete registration and other procedural steps. As fundraising projects advance and more commercial orders are secured, a key market focus will remain on whether humanoid robots can successfully transition from demonstration and pilot phases to widespread commercial application.
Risk Warning: This article is provided for informational purposes only and does not constitute investment advice, investment research, or a recommendation to trade. The views expressed are those of the author and do not necessarily reflect the position of Markets.com. When considering shares, indices, forex (foreign exchange), and commodities for trading and price predictions, remember that trading CFDs involves a significant degree of risk and may not be suitable for all investors. Leveraged products can result in capital loss. Past performance is not indicative of future results. Before trading, ensure you fully understand the risks involved and consider your investment objectives and level of experience. Cryptocurrency CFD trading restrictions may apply depending on jurisdiction.